Dallah Healthcare (4004) Stock Overview
Operates as a health care company in the Kingdom of Saudi Arabia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
4004 Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Dallah Healthcare Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ر.س123.60 |
| 52 Week High | ر.س164.00 |
| 52 Week Low | ر.س109.00 |
| Beta | 0.066 |
| 1 Month Change | -14.52% |
| 3 Month Change | -3.44% |
| 1 Year Change | -20.77% |
| 3 Year Change | -22.26% |
| 5 Year Change | 154.58% |
| Change since IPO | 261.20% |
Recent News & Updates
Dallah Healthcare Company Just Beat EPS By 11%: Here's What Analysts Think Will Happen Next
Nov 15
Dallah Healthcare (TADAWUL:4004) Is Experiencing Growth In Returns On Capital
Oct 15Recent updates
Dallah Healthcare Company Just Beat EPS By 11%: Here's What Analysts Think Will Happen Next
Nov 15Dallah Healthcare (TADAWUL:4004) Is Experiencing Growth In Returns On Capital
Oct 15Some Shareholders Feeling Restless Over Dallah Healthcare Company's (TADAWUL:4004) P/E Ratio
Sep 02If EPS Growth Is Important To You, Dallah Healthcare (TADAWUL:4004) Presents An Opportunity
Aug 02Dallah Healthcare's (TADAWUL:4004) Returns On Capital Are Heading Higher
May 09Do Dallah Healthcare's (TADAWUL:4004) Earnings Warrant Your Attention?
Apr 20What Dallah Healthcare Company's (TADAWUL:4004) P/E Is Not Telling You
Feb 13Investors Will Want Dallah Healthcare's (TADAWUL:4004) Growth In ROCE To Persist
Jan 08With EPS Growth And More, Dallah Healthcare (TADAWUL:4004) Makes An Interesting Case
Dec 21Some Shareholders Feeling Restless Over Dallah Healthcare Company's (TADAWUL:4004) P/E Ratio
Oct 31The Return Trends At Dallah Healthcare (TADAWUL:4004) Look Promising
Oct 07Do Dallah Healthcare's (TADAWUL:4004) Earnings Warrant Your Attention?
Sep 19Dallah Healthcare Company (TADAWUL:4004) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 14The Price Is Right For Dallah Healthcare Company (TADAWUL:4004)
Jul 18Investors Will Want Dallah Healthcare's (TADAWUL:4004) Growth In ROCE To Persist
May 30We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease
Apr 16What You Can Learn From Dallah Healthcare Company's (TADAWUL:4004) P/E
Mar 18Returns On Capital At Dallah Healthcare (TADAWUL:4004) Have Hit The Brakes
Feb 25Dallah Healthcare (TADAWUL:4004) Has More To Do To Multiply In Value Going Forward
Oct 30Dallah Healthcare (TADAWUL:4004) Is Reinvesting At Lower Rates Of Return
Jul 26Returns On Capital Signal Tricky Times Ahead For Dallah Healthcare (TADAWUL:4004)
Apr 17Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?
Feb 06Dallah Healthcare (TADAWUL:4004) Will Want To Turn Around Its Return Trends
Dec 05We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease
Nov 01Calculating The Intrinsic Value Of Dallah Healthcare Company (TADAWUL:4004)
Aug 28Dallah Healthcare (TADAWUL:4004) Has Some Way To Go To Become A Multi-Bagger
Aug 12Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching
Jul 28Industry Analysts Just Upgraded Their Dallah Healthcare Company (TADAWUL:4004) Revenue Forecasts By 10%
May 26Calculating The Fair Value Of Dallah Healthcare Company (TADAWUL:4004)
May 20Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching
Apr 16Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively
Feb 03Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?
Jan 10Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively
Oct 19Shareholder Returns
| 4004 | SA Healthcare | SA Market | |
|---|---|---|---|
| 7D | -1.7% | 3.5% | -0.1% |
| 1Y | -20.8% | -21.2% | -12.9% |
Return vs Industry: 4004 matched the SA Healthcare industry which returned -21.2% over the past year.
Return vs Market: 4004 underperformed the SA Market which returned -12.9% over the past year.
Price Volatility
| 4004 volatility | |
|---|---|
| 4004 Average Weekly Movement | 4.5% |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in SA Market | 7.3% |
| 10% least volatile stocks in SA Market | 2.5% |
Stable Share Price: 4004 has not had significant price volatility in the past 3 months compared to the SA market.
Volatility Over Time: 4004's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Ahmad bin Babaeer | www.dallahhealth.com |
Dallah Healthcare Company operates as a health care company in the Kingdom of Saudi Arabia. The company engages in operating, managing, equipping, and developing hospitals and healthcare facilities, medical centres, complexes, and clinics; and the provision of manpower and support services. It manufactures and distributes pharmaceutical, herbal and cosmetic products, and toiletries.
Dallah Healthcare Company Fundamentals Summary
| 4004 fundamental statistics | |
|---|---|
| Market cap | ر.س12.51b |
| Earnings (TTM) | ر.س535.63m |
| Revenue (TTM) | ر.س3.77b |
Is 4004 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4004 income statement (TTM) | |
|---|---|
| Revenue | ر.س3.77b |
| Cost of Revenue | ر.س2.49b |
| Gross Profit | ر.س1.27b |
| Other Expenses | ر.س736.97m |
| Earnings | ر.س535.63m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.29 |
| Gross Margin | 33.80% |
| Net Profit Margin | 14.23% |
| Debt/Equity Ratio | 70.7% |
How did 4004 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/08 23:41 |
| End of Day Share Price | 2025/12/08 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dallah Healthcare Company is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ibrahim Elaiwat | Aljazira Capital Company |
| Jassim Al-Jubran | Aljazira Capital Company |
| Rim Ben Salah Gharbi | AlphaMena |